Skip to main content

Resmed Value Stock - Dividend - Research Selection

Resmed

ISIN: US7611521078 , WKN: 895878

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Citigroup Maintains Buy on ResMed, Lowers Price Target to $340

2026-04-09
Citigroup analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Buy and lowers the price target from $345 to $340.

Global Anesthesia and Respiratory Devices Market Size/Share Worth USD 100.5 Billion by 2035 at a 5.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)

2026-04-07
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Anesthesia and Respiratory Devices Market size & share revenue was valued at approximately USD 57.2 Billion in 2025 and is expected to reach USD 60.5 Billion in 2026 and is expected to reach around USD 100.5 Billion by 2035, at a CAGR of 5.8% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Medtronic, O2

Top 50 High-Quality Dividend Growth Stocks For April 2026

2026-04-07
I track a universe of 50 high-quality dividend growth stocks to identify attractive entry points based on updated valuations and forward return estimates.

I Shared 42 Sell Ratings In 2019. Here Is How They Have Performed Long-Term.

2026-04-07
Tested 42 S&P 500 “Sell” ratings with Full-Cycle Analysis: most underperformed SPY/RSP over 6–7 years, helping spot overvalued stocks.

Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026

2026-04-01
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:https://investor.resmed.com•Date

ResMed Inc. stock rises Tuesday, still underperforms market

2026-03-31
ResMed Inc. stock rises Tuesday, still underperforms market

Is It Time To Revisit ResMed (RMD) After Recent Share Price Weakness?

2026-03-31
Wondering whether ResMed at around US$220 a share looks like a bargain or a potential value trap? This article walks through what the current price actually reflects about the business. The stock has been volatile recently, with a 3.5% decline over the last 7 days, a 14.1% decline over 30 days, and returns of 10.1% lower year to date. The 1 year return sits at 0.8% lower and the 3 and 5 year returns are 3.3% and 17.7% respectively. These moves have kept attention on how the market is pricing...

4 GARP Stocks That Investors Can Scoop Up for Maximum Returns

2026-03-30
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. NVDA, RL, RMD and GE hold promise.

ResMed Earnings Preview: What to Expect

2026-03-30
ResMed is set to announce its third-quarter earnings soon, and Wall Street expects the company’s EPS to increase by double digits.

Unpacking Q4 Earnings: ResMed (NYSE:RMD) In The Context Of Other Patient Monitoring Stocks

2026-03-26
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at patient monitoring stocks, starting with ResMed (NYSE:RMD).